Related Experiment Videos
BO-653. Chugai
1AtheroGenics Inc, 8995 Westside Parkway, Alpharetta, GA 30004, USA. Cmeng@atherogenics.com
Current Opinion in Investigational Drugs (London, England : 2000)
|May 9, 2003
Summary
BO-653, an antioxidant, is being developed for atherosclerosis and restenosis prevention. Clinical trials in the US and Japan are evaluating its potential in treating these cardiovascular conditions.
Area of Science:
- Cardiovascular pharmacology
- Drug development
- Antioxidant research
Background:
- Atherosclerosis is a major cardiovascular disease.
- Restenosis after angioplasty poses a significant clinical challenge.
- Antioxidants show potential in managing vascular conditions.
Purpose of the Study:
- To evaluate the efficacy of BO-653 in preventing restenosis.
- To assess the safety and tolerability of BO-653 in clinical trials.
- To explore the therapeutic potential of BO-653 for atherosclerosis.
Main Methods:
- Phase II clinical trials for restenosis prevention post-angioplasty in the US.
- Phase I clinical trials for restenosis in Japan.
- Pharmacological studies on antioxidant properties of BO-653.
Main Results:
- BO-653 is under active clinical investigation for cardiovascular applications.
- Trial data will determine the compound's efficacy and safety profile.
- Ongoing research focuses on BO-653's role in vascular health.
Conclusions:
- BO-653 demonstrates potential as a therapeutic agent for cardiovascular diseases.
- Further clinical evaluation is necessary to establish its role in treatment.
- The development of BO-653 highlights ongoing efforts in cardiovascular drug discovery.